Phase II study of durvalumab following neoadjuvant chemoRT in operable rectal cancer: NSABP FR-2.

医学 结直肠癌 杜瓦卢马布 临床终点 内科学 肿瘤科 临床研究阶段 放化疗 代理终结点 放射治疗 癌症 免疫疗法 泌尿科 临床试验 无容量
作者
Thomas J. George,Greg Yothers,Samuel A. Jacobs,Gene Grant Finley,James L. Wade,Caio Max Sao Pedro Rocha Lima,Jeffrey S. Rose,Shalu Pahuja,Anuradha Krishnamurthy,John C. Krauss,Melvin Deutsch,Jesus C. Fabregas,James J. Lee,Carmen J. Allegra,Norman Wolmark
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:40 (4_suppl): 99-99 被引量:28
标识
DOI:10.1200/jco.2022.40.4_suppl.099
摘要

99 Background: Although immunotherapy shows no benefit in microsatellite stable (MSS) colorectal cancer, preclinical models suggest that radiotherapy (RT) can enhance neoantigen presentation, modulate the microenvironment, and improve the likelihood of anti-tumor activity with checkpoint inhibitor use. Using a “window-of-opportunity” study design, this prospective phase II trial will determine the safety and activity of this approach with the anti-PD-L1 agent durvalumab (MEDI4736). Methods: Stage II/III patients (pts) with MSS rectal cancer undergoing standard NCCN guideline-compliant neoadjuvant chemoradiotherapy (CRT) followed by definitive surgery were eligible. Treatment included durvalumab (750mg IV infusion once every 2 wks) for 4 total doses beginning within 3-7 days after CRT completion followed by surgery within 8-12 wks of the final CRT dose. Primary end point (EP): Improvement in modified neoadjuvant rectal cancer (mNAR) score (goal 10.6) compared to historical controls (15.6) targeting a 20% DFS RR reduction and 3-4% absolute OS improvement. Secondary EPs: toxicity, pCR, cCR, therapy completion, negative surgical margins, sphincter preservation, and exploratory assessments of tumor-infiltrating lymphocytes, tumor Immunoscore, circulating immunologic profiles, and molecular predictors of response. We test H 0 : mNAR ≥15.6 vs H A : mNAR <15.6 at alpha 0.10 one-sided with statistical significance defined as p<0.1. Results: From May 2018 to October 2020, 45 pts were enrolled with 40 pts evaluable for mNAR. Mean mNAR was 12.03 (80% CI: 9.29-14.97) (p=0.06 one-sided). pCR=22.2%; cCR=31.1%; R0 resection=81.0%, and sphincter preservation=71.4%. Side effects were consistent with both CRT and durvalumab safety profile. Most common grade 3 AEs included diarrhea, lymphopenia, and back pain. There was one grade 4 AE (elevated amylase/lipase) and no grade 5 AEs. Remaining secondary and correlative immunologic end points are still being assessed. Conclusions: Durvalumab immediately following CRT prior to surgery for definitive management of rectal cancer was safe and without unexpected short-term toxicities. The primary end point of mean mNAR score was significantly less than our historical control, warranting further investigation. Correlative analyses for immunologic markers of response including PD-(L)1 expression and Immunoscore are ongoing. NCT 03102047. Support: AstraZeneca-Medimmune, NSABP Foundation. Clinical trial information: NCT03102047.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI6.4的应助被开心德地采纳,获得50
1秒前
1秒前
1秒前
爆米花的应助被之昂强尼采纳,获得10
2秒前
Zhou完成签到,获得积分10
3秒前
3秒前
求助文献完成签到,获得积分20
3秒前
4秒前
Desirable发布了新的文献求助10
4秒前
李健的小迷弟的应助被YX_J采纳,获得10
6秒前
pokexuejiao发布了新的文献求助10
7秒前
海阔天空发布了新的文献求助10
7秒前
科研通AI6.3的应助被吃的采纳,获得10
7秒前
梁芯发布了新的文献求助10
8秒前
9秒前
yu发布了新的文献求助10
10秒前
jwin发布了新的文献求助10
11秒前
栗子卷完成签到 ,获得积分10
12秒前
12秒前
刘丹黎完成签到,获得积分10
13秒前
13秒前
英俊的铭的应助被开心德地采纳,获得10
13秒前
单薄冰安发布了新的文献求助10
15秒前
苗条的夜梦完成签到,获得积分10
16秒前
16秒前
搞怪建辉完成签到,获得积分10
16秒前
etheral完成签到 ,获得积分10
17秒前
鱼梓发布了新的文献求助10
17秒前
17秒前
18秒前
情怀的应助被Jacky采纳,获得10
18秒前
小燕尾条发布了新的文献求助10
18秒前
hjhhjh完成签到,获得积分10
19秒前
19秒前
19秒前
20秒前
风有约完成签到 ,获得积分10
21秒前
22秒前
踏实凡桃发布了新的文献求助10
22秒前
共享精神的应助被开心德地采纳,获得10
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188654
求助须知:如何正确求助?哪些是违规求助? 9576372
关于积分的说明 21847161
捐赠科研通 7786741
什么是DOI,文献DOI怎么找? 3435402
关于科研通互助平台的介绍 2559632
邀请新用户注册赠送积分活动 2482360